Larimar Therapeutics Inc. (LRMR)
2.64
-0.39 (-12.87%)
At close: Mar 03, 2025, 3:59 PM
2.65
0.38%
After-hours: Mar 03, 2025, 04:54 PM EST
Larimar Therapeutics Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 311K | 272K | 326K | 155K | 78K | 261K | 188K | 212K | 70K | n/a | 12K | 11K | 4K |
| Gross Profit | -311K | -272K | -326K | -155K | -78K | -261K | -188K | -212K | -70K | n/a | -12K | -11K | -4K |
| Operating Income | -41.76M | -36.53M | -50.47M | -42.8M | -23.21M | -62.72M | -53.88M | -57.12M | -73.81M | -35.53M | -13.78M | -13.79M | -13.15M |
| Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | 996K | 894K | 438K | 28K | n/a | n/a | n/a |
| Pretax Income | -36.95M | -35.35M | -50.64M | -42.48M | -23.13M | -62.97M | -52.93M | -58.18M | -74.29M | -36.57M | -14.03M | -13.88M | -13.16M |
| Net Income | -36.95M | -34.18M | -50.31M | -42.33M | -23.13M | -61.37M | -52.03M | -57.88M | -74.29M | -36.57M | -14.03M | -13.88M | -13.16M |
| Selling & General & Admin | 14.09M | 12.28M | 12.07M | 11.4M | 2.42M | 12.93M | 11.95M | 17.14M | 19.13M | 8.14M | 4.21M | 2.24M | 1.75M |
| Research & Development | 27.36M | 24.25M | 38.4M | 31.41M | 20.79M | 49.53M | 41.74M | 39.77M | 54.62M | 27.39M | 9.56M | 11.54M | 11.4M |
| Other Expenses | n/a | 1.17M | -171K | 322K | 82K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Expenses | 41.76M | 36.53M | 50.47M | 42.8M | 23.21M | 62.46M | 53.69M | 56.91M | 73.74M | 35.53M | 13.77M | 13.78M | 13.15M |
| Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | 971K | 347K | 806K | -870K | n/a | 97K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | 12.93M | -212K | -1.15M | -70K | n/a | n/a | n/a | n/a |
| Cost & Expenses | 41.76M | 36.53M | 50.47M | 42.8M | 23.21M | 62.72M | 53.88M | 57.12M | 73.81M | 35.53M | 13.78M | 13.79M | 13.15M |
| Income Tax | n/a | -1.17M | -326K | -155K | -93.86K | -1.6M | -900K | -300K | -946K | n/a | n/a | n/a | n/a |
| Shares Outstanding (Basic) | 43.9M | 25.76M | 17.16M | 11.88M | 9.21M | 2.69M | 2.29M | 2.27M | 2.23M | 2.42M | 2.18M | 2.18M | 2.18M |
| Shares Outstanding (Diluted) | 43.9M | 25.76M | 17.16M | 11.88M | 9.21M | 2.69M | 2.29M | 2.27M | 2.23M | 2.42M | 2.18M | 2.18M | 2.18M |
| EPS (Basic) | -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 | -6.54 | -6.4 | -6.07 |
| EPS (Diluted) | -0.84 | -1.33 | -2.93 | -3.56 | -2.51 | -22.85 | -22.76 | -25.44 | -33.32 | -15.14 | -6.54 | -6.4 | -6.07 |
| EBITDA | -41.45M | -35.08M | -50.14M | -42.65M | -23.14M | -60.81M | -52.58M | -57.44M | -73.41M | -35.53M | -14.02M | -13.77M | -13.15M |
| Depreciation & Amortization | 311K | 272K | 326K | 155K | 78K | 261K | 188K | 212K | 70K | n/a | 12K | 11K | 4K |